Cure8 research brief
Modeled cost savings and fewer hospital visits could affect access to infliximab for people with Crohn’s disease and other autoimmune conditions in Jordan, potentially increasing the number of patients who can be treated and reducing burdens on clinics.
Payers and policy makers in Jordan and similar settings, clinicians who prescribe biologics, patients on or considering infliximab, and health economists.
The article presents a prevalence-based budget impact model from a payer perspective in Jordan, comparing a base case (no IFX SC) to scenarios with full or gradual adoption of IFX SC over five years. Cost inputs, eligible patient numbers, and market-share assumptions were taken from official sources; sensitivity analyses were performed to test robustness.
Reported findings are modeled cost savings and increased eligible patient counts, not clinical effectiveness comparisons. Practical takeaways The economic case described supports consideration of IFX SC reimbursement in this health system because of modeled savings and potential convenience benefits.
The authors emphasize that real-world evidence is still needed on comparative effectiveness, patient tolerability, and clinical acceptance before assuming equivalent clinical outcomes. Summary confidence: medium
This is a modeling study (budget impact analysis) using country-specific inputs and assumptions; it reports projected cost outcomes rather than clinical trial results. The authors note that real-world evidence on effectiveness, tolerability, and uptake is needed to address remaining uncertainties.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Label updates for INFLECTRA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and safety warnings for a commonly used anti-TNF biologic/biosimilar. The label...
Label changes for RENFLEXIS affect people with Crohn's disease or ulcerative colitis who take (or may be prescribed) infliximab biosimilars — the label includes dosing, age indications, and important safety warnings that...
Label updates for AVSOLA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and important safety warnings (infection, TB, hepatitis B, and lymphoma risk) that guide...
